Malignant Mesothelioma

1. Clinical Overview

Summary

Malignant Mesothelioma (MM) is an aggressive, typically incurable neoplasm arising from the mesothelial cells lining serosal surfaces, predominantly the pleura (approximately 90% of cases), with less common involvement of the peritoneum, pericardium, and tunica vaginalis. [1]

This malignancy is intrinsically linked to asbestos exposure, with a characteristic latency period of 20-50 years between first exposure and clinical presentation. Due to peak asbestos utilization in the industrialized world during the 1960s-1980s, incidence rates are currently at or approaching their peak in countries such as the United Kingdom, Australia, and parts of Western Europe. [2,3]

The therapeutic landscape for mesothelioma has undergone a paradigm shift in recent years. Immunotherapy with dual checkpoint inhibition (ipilimumab plus nivolumab) has demonstrated superior outcomes compared to traditional platinum-based chemotherapy and has become the preferred first-line treatment for most patients with unresectable disease. [4] Conversely, the role of radical cytoreductive surgery has been substantially questioned following the MARS 2 trial results, which showed no survival benefit and increased morbidity with surgical intervention. [5]

Despite therapeutic advances, mesothelioma remains a disease with poor prognosis, with median survival ranging from 12-18 months depending on histological subtype, disease extent, and performance status. Management is inherently multidisciplinary, involving respiratory physicians, oncologists, thoracic surgeons, palliative care specialists, and occupational health services. [6]

Clinical Pearls

The "Frozen Hemithorax": On physical examination, a patient with advanced mesothelioma often presents with a hemithorax that demonstrates markedly reduced or absent respiratory excursion. The tumor forms a restrictive "rind" or "peel" that encases the lung parenchyma, preventing normal expansion even after therapeutic thoracentesis. This finding is pathognomonic and distinguishes mesothelioma from simple malignant effusions.

Procedural Tract Metastasis: Mesothelioma exhibits a unique propensity for seeding along instrumentation tracts, including sites of pleural biopsy, chest drain insertion, and thoracoscopy ports. This phenomenon manifests as subcutaneous nodules developing weeks to months after procedures. The PIT (Prophylactic Irradiation of Tracts) Trial definitively demonstrated that prophylactic radiotherapy to procedure sites does not reduce the incidence of tract metastases and is no longer recommended. [7]

The "Boring" Pain: Unlike the sharp, pleuritic pain associated with acute pleural inflammation, mesothelioma-related chest wall invasion produces a deep, gnawing, "toothache-like" quality of pain. This reflects neuropathic involvement of intercostal nerves and is notoriously difficult to manage, often requiring strong opioids (including methadone) combined with neuropathic agents such as gabapentin or pregabalin.

Clubbing Paradox: Finger clubbing is paradoxically rare in mesothelioma (present in less than 5% of cases), despite its frequency in asbestosis and primary lung cancer. When clubbing is present in a patient with asbestos exposure and pleural disease, concomitant lung cancer or asbestosis should be strongly considered.

---

2. Epidemiology

Global Incidence Patterns

Malignant mesothelioma demonstrates striking geographic variation in incidence, directly reflecting historical patterns of asbestos use and occupational exposure. [2]

High-Incidence Regions:

• United Kingdom: ~2,500 deaths annually (age-standardized rate: 4.5 per 100,000 males)
• Australia: Age-standardized rate of 4.3 per 100,000, highest in Western Australia
• Netherlands, Belgium: Rates exceeding 3 per 100,000 due to historical shipbuilding and construction industries

Emerging Epidemic Regions:

• India, China, Russia: Rising incidence anticipated over the next 20-30 years due to ongoing asbestos use and lack of regulatory controls [3]

Demographics

• Age: Median age at diagnosis is 72 years; exceptionally rare below age 40
• Gender: Male predominance (M:F ratio approximately 4-5:1), reflecting occupational exposure patterns
• Latency Period: Typically 30-50 years from first exposure to diagnosis, though cases with latency less than 15 years or > 60 years are documented
• Temporal Trends: Incidence in the UK and Western Europe is at or near peak and is projected to decline by 2030-2040

Asbestos Fiber Types and Carcinogenic Potential

Not all asbestos fibers carry equal risk. Fiber dimensions, biopersistence, and surface chemistry determine carcinogenic potential. [8]

Amphiboles (Needle-Shaped, Straight Fibers):

• Crocidolite (Blue Asbestos): Highest mesothelioma risk (relative risk 10-fold greater than chrysotile)
• Amosite (Brown Asbestos): Second highest risk
• Anthophyllite, Tremolite, Actinolite: Less commonly used but highly carcinogenic

Amphibole fibers are resistant to macrophage-mediated clearance and chemical degradation, leading to prolonged retention in pleural tissue.

Serpentines (Curved, Flexible Fibers):

• Chrysotile (White Asbestos): Comprises > 95% of commercially used asbestos globally
• Curved structure facilitates partial clearance by mucociliary mechanisms
• Carcinogenic potential remains controversial but is substantially lower than amphiboles
• Still capable of causing mesothelioma, particularly with heavy or prolonged exposure

Occupational and Environmental Exposure

High-Risk Occupations:

• Shipbuilding and naval dockyards (especially 1940s-1980s)
• Asbestos mining and milling
• Construction and demolition workers
• Insulation and pipe-fitting trades
• Railway carriage manufacturing
• Automotive brake lining manufacture

Non-Occupational Exposure:

• Household contact exposure (e.g., washing contaminated work clothes)
• Environmental exposure from proximity to asbestos mines or manufacturing plants
• Natural asbestos deposits (e.g., Cappadocia region of Turkey, New Caledonia)

Non-Asbestos Causes (Rare):

• Therapeutic radiation (typically > 30 Gy, latency 15-30 years)
• Erionite (naturally occurring fibrous mineral, endemic in Turkish villages)
• Germline BAP1 mutations (cancer predisposition syndrome) [9]

---

3. Pathophysiology

Mechanisms of Asbestos-Induced Carcinogenesis

The development of mesothelioma involves complex interactions between asbestos fibers, mesothelial cells, immune cells, and the tumor microenvironment. [10]

Step 1: Fiber Inhalation and Migration

1. Deposition: Asbestos fibers small enough to reach the alveoli (length less than 10 μm, diameter less than 0.5 μm) deposit in the distal airways
2. Translocation: Fibers penetrate the visceral pleura through:
   • Direct penetration of lung parenchyma
   • Lymphatic drainage to pleural space
   • Migration along interstitial tissue planes

Step 2: "Frustrated Phagocytosis" and Chronic Inflammation

Alveolar macrophages and pleural mesothelial cells attempt to engulf asbestos fibers but fail due to fiber length exceeding phagocytic capacity. This results in:

• Chronic Release of Reactive Oxygen Species (ROS): Superoxide, hydrogen peroxide, hydroxyl radicals
• Pro-inflammatory Cytokine Production: TNF-α, IL-1β, IL-6, TGF-β
• Growth Factor Secretion: PDGF, VEGF promoting fibrosis and angiogenesis

This process continues for decades, creating a pro-carcinogenic microenvironment.

Step 3: DNA Damage and Genomic Instability

Direct and indirect mechanisms of DNA damage include:

• Physical Interference: Asbestos fibers disrupt mitotic spindle formation, causing chromosomal segregation errors
• ROS-Mediated Damage: Oxidative DNA base modifications, strand breaks
• Impaired DNA Repair: Asbestos interferes with nucleotide excision repair pathways

Step 4: Loss of Tumor Suppressor Function

Recurrent genetic alterations in mesothelioma include: [11]

BAP1 (BRCA1-Associated Protein 1):

• Inactivating mutations or deletions in > 60% of mesotheliomas
• Encodes a deubiquitinating enzyme involved in DNA repair, cell cycle regulation, and chromatin remodeling
• Germline BAP1 mutations confer familial cancer predisposition (mesothelioma, uveal melanoma, renal cell carcinoma)

NF2 (Neurofibromin 2/Merlin):

• Inactivated in ~40-50% of cases
• Encodes a cytoskeletal protein that inhibits proliferative signaling through Hippo pathway dysregulation

CDKN2A (p16):

• Homozygous deletions in ~70% of cases
• Loss of cell cycle checkpoint control

TP53:

• Unlike most solid tumors, TP53 mutations are infrequent in mesothelioma (~10-20%)

Molecular Subtypes

Transcriptomic profiling identifies distinct molecular subtypes with prognostic implications: [12]

• Epithelioid Subtype: Enrichment of Wnt/β-catenin signaling, better immunotherapy response
• Sarcomatoid Subtype: Upregulation of epithelial-mesenchymal transition (EMT) pathways, immune "cold" phenotype
• Biphasic Subtype: Heterogeneous admixture of both patterns

---

4. Clinical Presentation

Histological Classification and Prognostic Implications

The World Health Organization (WHO) classification recognizes three major histological subtypes: [13]

1. Epithelioid Mesothelioma (60-70%)

Morphology:

• Cuboidal to columnar cells forming tubular, papillary, or solid growth patterns
• May exhibit diverse architectural patterns: tubulopapillary, adenomatoid, solid, trabecular

Prognosis:

• Best of all subtypes
• Median survival with modern therapy: 18-24 months

Differential Diagnosis:

• Adenocarcinoma (particularly lung or breast primary)
• Reactive mesothelial hyperplasia

2. Sarcomatoid Mesothelioma (10-20%)

Morphology:

• Spindle cells with fascicular or storiform architecture
• May contain heterologous elements (osteosarcomatous, chondrosarcomatous differentiation)
• High mitotic rate, marked cytologic atypia

Prognosis:

• Poorest prognosis among subtypes
• Historically resistant to chemotherapy
• Median survival with chemotherapy: 4-8 months
• Improved outcomes with immunotherapy (median survival 18 months with ipilimumab-nivolumab) [4]

Clinical Note:

• Often misdiagnosed as sarcoma or fibrous tumor on small biopsies
• Immunohistochemistry essential for diagnosis

3. Biphasic Mesothelioma (20-30%)

Morphology:

• Contains both epithelioid and sarcomatoid components
• Each component must comprise ≥10% of tumor volume

Prognosis:

• Intermediate, influenced by the percentage of sarcomatoid component
• Tumors with > 50% sarcomatoid elements behave more aggressively

Clinical Symptoms

Primary Respiratory Symptoms

Dyspnoea (90% of patients):

• Initially related to pleural effusion
• Progresses to restrictive lung disease from pleural rind encasement
• May be exacerbated by associated asbestosis (restrictive lung disease) or COPD (common comorbidity in smokers with asbestos exposure)

Chest Pain (60-70%):

• Non-pleuritic, dull, aching quality in early disease
• Progressive to severe, neuropathic pain with chest wall invasion
• Distribution may follow dermatomal pattern with intercostal nerve involvement
• Often refractory to standard analgesics

Cough (25-30%):

• Usually non-productive
• Less prominent than in primary lung cancer

Constitutional Symptoms (Advanced Disease)

• Weight Loss: Unintentional loss > 10% body weight (poor prognostic sign)
• Fatigue and Malaise: Related to cancer cachexia, chronic inflammation
• Night Sweats: Less common than in lymphoma but may occur
• Fever: Rare, suggests concurrent infection or paraneoplastic phenomenon

Site-Specific Presentations

Peritoneal Mesothelioma (5-10% of cases):

• Abdominal distension (ascites)
• Abdominal pain, often insidious onset
• Bowel obstruction (late complication)
• Male predominance less pronounced (M:F ratio ~2:1)
• May occur without prior pleural disease

Pericardial Mesothelioma (less than 1% of cases):

• Dyspnoea, chest pain
• Pericardial effusion, tamponade
• Constrictive physiology
• Extremely poor prognosis (median survival 2-6 months)

Testicular Mesothelioma (Tunica Vaginalis, less than 1% of cases):

• Painless scrotal swelling, hydrocele
• Often diagnosed incidentally at hernia repair or hydrocelectomy
• Better prognosis than pleural mesothelioma (5-year survival 50-60%)

---

5. Clinical Examination

Respiratory Examination Findings

Inspection:

• Reduced Chest Wall Excursion: Hemithorax may appear "frozen" with minimal or absent respiratory movement
• Surgical Scars: Previous thoracoscopy, biopsy, or drain sites
• Subcutaneous Nodules: Tract metastases along previous procedural sites
• Cachexia: Temporal wasting, loss of muscle bulk

Palpation:

• Reduced Expansion: Asymmetrical chest expansion on affected side
• Tactile Fremitus: Reduced (due to effusion or pleural thickening)

Percussion:

• Stony Dullness: Classic finding of large pleural effusion
• Unilateral Dullness: Entire hemithorax may be dull if encased

Auscultation:

• Reduced Breath Sounds: Over effusion or thickened pleura
• Bronchial Breathing: May be heard at upper border of effusion
• Pleural Rub: Uncommon (more typical of acute pleuritis)

Signs of Advanced Disease

Superior Vena Cava Obstruction (5-10%):

• Facial and upper limb edema
• Dilated veins over chest wall and neck
• Conjunctival suffusion
• Pemberton's sign positive

Horner's Syndrome:

• Ptosis, miosis, anhidrosis
• Indicates apical pleural involvement with sympathetic chain invasion

Phrenic Nerve Palsy:

• Elevated hemidiaphragm
• Paradoxical abdominal movement

Lymphadenopathy:

• Supraclavicular nodes (late dissemination)
• Axillary nodes (less common)

Extrathoracic Manifestations

Clubbing:

• Paradoxically rare in mesothelioma (less than 5%)
• When present, suggests concurrent asbestosis or lung cancer

Abdominal Examination:

• Ascites (peritoneal involvement)
• Hepatomegaly (metastatic disease)
• Omental mass (peritoneal mesothelioma)

---

6. Investigations

Initial Investigations

Chest Radiography

Typical Findings:

• Unilateral Pleural Effusion (80-90% at presentation)
• Nodular or Lobulated Pleural Thickening
• Volume Loss of affected hemithorax
• Mediastinal Shift: Towards affected side (unlike typical effusion which shifts away)
• Pleural Plaques: Bilateral calcified plaques indicate asbestos exposure but do not diagnose mesothelioma

Radiographic Pitfalls:

• Early disease may appear as minimal pleural thickening
• Difficult to distinguish from benign asbestos-related pleural disease on plain film alone

Blood Tests

Routine Investigations:

• Full Blood Count: Anemia (chronic disease), thrombocytosis (paraneoplastic, poor prognostic marker)
• Renal Function: Baseline before nephrotoxic chemotherapy
• Liver Function Tests: Assess for metastatic disease

Tumor Markers (Limited Sensitivity):

• Serum Mesothelin-Related Peptide (SMRP): Elevated in 60-80% of cases [14]
  • Sensitivity too low for screening
  • Useful for monitoring treatment response and recurrence
  • Elevated in benign pleural disease (reduces specificity)
• Fibulin-3: Emerging biomarker, not yet in routine use
• Osteopontin: Research tool, not clinically validated

Cross-Sectional Imaging

Contrast-Enhanced CT Thorax

Gold Standard for Initial Assessment

Findings Suggestive of Mesothelioma: [15]

• Circumferential Pleural Thickening (nodular, > 1 cm thickness)
• "Pleural Rind": Continuous sheet encasing lung
• Mediastinal Pleural Involvement: Strong predictor of mesothelioma (not typical of metastatic disease)
• Interlobar Fissure Thickening
• Volume Loss: Hemithorax contraction with mediastinal shift towards lesion
• Chest Wall Invasion: Soft tissue extension beyond ribs
• Diaphragmatic Involvement

Features Distinguishing from Metastatic Pleural Disease:

• Metastases typically spare mediastinal pleura
• Metastases associated with primary lung mass or contralateral disease

PET-CT

Indications:

• Staging of disease (assessment for distant metastases)
• Evaluation of suitability for radical surgery (largely historical given MARS 2 results)
• Differentiation of benign vs. malignant pleural thickening (limited specificity)

Findings:

• High FDG uptake (SUVmax typically > 5)
• Sarcomatoid subtype often shows higher uptake than epithelioid
• False positives: Tuberculosis, empyema, talc pleurodesis

Limitations:

• Cannot reliably distinguish mesothelioma from other malignancies
• Poor sensitivity for peritoneal disease

MRI Thorax

Indications (Selected Cases):

• Assessment of diaphragmatic invasion
• Evaluation of chest wall and mediastinal involvement
• Differentiation from benign disease (e.g., organizing hemothorax)
• Patients with contraindications to CT contrast

Advantages:

• Superior soft tissue contrast
• No ionizing radiation

Limitations:

• Not widely used due to cost, availability, motion artifact

Pleural Fluid Analysis

Thoracentesis

Macroscopic Appearance:

• Typically bloody or serosanguinous (exudate)
• Large volume (often > 1 liter)

Biochemistry:

• Exudative by Light's criteria
• Protein > 30 g/L
• LDH elevated
• pH typically > 7.3 (unlike empyema)
• Glucose normal (unlike rheumatoid effusion or empyema)

Cytology:

• Sensitivity: 20-30% (poor)
• Challenges:
  • Mesothelioma cells resemble reactive mesothelial cells
  • Architectural invasion cannot be assessed on fluid cytology
  • Requires tissue biopsy showing invasion for definitive diagnosis

Immunocytochemistry (If Cells Available):

• Positive: Calretinin, CK5/6, WT-1, D2-40
• Negative: TTF-1, Napsin A, CEA (helps exclude adenocarcinoma)

Tissue Diagnosis (Essential)

Pleural Biopsy Techniques

1. Image-Guided Core Needle Biopsy (CT or Ultrasound):

• Indications: Accessible pleural mass, unfit for thoracoscopy
• Technique: 14-16 gauge core needle, multiple passes
• Sensitivity: 80-85%
• Advantages: Minimally invasive, outpatient procedure
• Disadvantages: Small sample size, may be inadequate for subtype classification

2. Medical Thoracoscopy (Pleuroscopy):

• Technique: Performed under conscious sedation, single port entry
• Sensitivity: > 90%
• Advantages:
  • Direct visualization and targeted biopsies
  • Simultaneous talc poudrage pleurodesis
  • Lower cost than VATS
• Disadvantages: Limited access to loculated or heavily scarred pleura

3. Video-Assisted Thoracoscopic Surgery (VATS):

• Technique: General anesthesia, multiple port entry
• Sensitivity: > 95%
• Advantages:
  • Larger biopsies
  • Access to all pleural surfaces
  • Ability to perform decortication if needed
• Disadvantages: Requires general anesthesia, higher cost

4. Open Pleural Biopsy (Thoracotomy):

• Rarely performed in modern practice
• Reserved for cases where VATS unsuccessful or unavailable

Histopathological Diagnosis

Immunohistochemistry Panel

Essential for distinguishing mesothelioma from adenocarcinoma and other mimics: [16]

Mesothelioma Markers (Positive):

• Calretinin: Highly sensitive (95-100%)
• WT-1: Sensitive (90-95%)
• CK5/6: Positive in epithelioid and biphasic types
• D2-40 (Podoplanin): Sensitive mesothelial marker

Adenocarcinoma Markers (Negative in Mesothelioma):

• TTF-1: Positive in lung adenocarcinoma
• Napsin A: Positive in lung adenocarcinoma
• CEA: Positive in many adenocarcinomas
• MOC-31 (Epithelial Cell Adhesion Molecule): Positive in adenocarcinoma

Diagnostic Criteria:

• ≥2 positive mesothelial markers AND ≥2 negative adenocarcinoma markers strongly support diagnosis
• Single marker insufficient due to heterogeneity

Molecular Testing (Emerging)

BAP1 Immunohistochemistry:

• Loss of nuclear BAP1 expression in ~60% of mesotheliomas
• Highly specific (retained in reactive mesothelium and most adenocarcinomas)
• Useful adjunct in difficult cases

CDKN2A (p16) Deletion (FISH):

• Homozygous deletion in ~70% of mesotheliomas
• Helpful in distinguishing malignant from reactive mesothelium

Methylthioadenosine Phosphorylase (MTAP):

• Loss of expression correlates with CDKN2A deletion
• IHC-based surrogate for FISH testing

Staging

TNM Classification (IMIG Staging, 8th Edition)

T Stage:

• T1: Ipsilateral parietal or visceral pleura
• T2: Diaphragmatic muscle or lung parenchyma invasion
• T3: Chest wall, mediastinal fat, or pericardium invasion
• T4: Contralateral pleura, peritoneum, or mediastinal organs

N Stage:

• N0: No lymph node involvement
• N1: Ipsilateral bronchopulmonary or hilar nodes
• N2: Ipsilateral mediastinal nodes
• N3: Contralateral or supraclavicular nodes

M Stage:

• M0: No distant metastases
• M1: Distant metastases

Stage Grouping:

• Stage I: T1 N0 M0
• Stage II: T2 N0 M0
• Stage III: T1-2 N1-2 M0 or T3 N0-2 M0
• Stage IV: T4 any N M0 or any T N3 M0 or any T any N M1

Clinical Utility:

• Staging primarily relevant for surgical case selection (rarely performed)
• Most patients present with Stage III-IV disease
• Performance status and histological subtype more important prognostic factors than anatomic stage

---

7. Management

Multidisciplinary Team (MDT) Approach

Every patient should be discussed at a specialist thoracic oncology MDT comprising:

• Respiratory physician
• Medical oncologist
• Thoracic surgeon
• Radiologist
• Pathologist
• Palliative care specialist
• Clinical nurse specialist
• Occupational health advisor (for compensation claims)

Management Algorithm

         SUSPECTED MESOTHELIOMA
         (Pleural thickening/effusion + asbestos exposure)
                      ↓
              CT THORAX (Contrast)
                      ↓
          TISSUE DIAGNOSIS REQUIRED
              ↓               ↓
    CT-Guided Biopsy    Thoracoscopy/VATS
              ↓               ↓
         CONFIRMED MESOTHELIOMA
         (Histology + IHC)
                      ↓
              STAGING (CT/PET)
          PERFORMANCE STATUS ASSESSMENT
                      ↓
      ┌───────────────┴───────────────┐
  PS 0-1 (Fit)                    PS ≥2 (Frail)
      ↓                                ↓
SYSTEMIC THERAPY             BEST SUPPORTIVE CARE
      ↓                                ↓
First-Line Options:            Symptom Management:
• Ipilimumab + Nivolumab       • Pleural drainage
  (Preferred)                  • Opioid analgesia
• Pemetrexed + Cisplatin       • Palliative RT
  (If ICI contraindicated)     • Early palliative care
      ↓
PLEURAL EFFUSION MANAGEMENT
      ↓
Recurrent Effusion?
      ↓
  ┌───┴────┐
YES         NO
  ↓          ↓
IPC or     Observation
Pleurodesis

Systemic Therapy

First-Line Immunotherapy (Standard of Care)

Ipilimumab + Nivolumab (CheckMate 743 Trial) [4]

Regimen:

• Nivolumab 3 mg/kg IV + Ipilimumab 1 mg/kg IV every 3 weeks for 4 cycles
• Followed by Nivolumab 240 mg IV every 2 weeks (or 480 mg every 4 weeks) as maintenance

Efficacy:

• Median overall survival: 18.1 months (vs. 14.1 months with chemotherapy)
• 2-year survival: 41% (vs. 27%)
• Greatest benefit in non-epithelioid subtypes:
  • "Sarcomatoid/biphasic: Median OS 18.1 months (vs. 8.8 months with chemo)"
  • Hazard ratio 0.46 in non-epithelioid histology

Indications:

• First-line therapy for unresectable mesothelioma
• PS 0-1 (selected PS 2 patients may be considered)
• No autoimmune contraindications

Adverse Effects:

• Immune-related adverse events (irAEs): 30% Grade 3-4
  • Pneumonitis, colitis, hepatitis, endocrinopathies, dermatitis
• Requires prompt recognition and corticosteroid therapy

Approved Indications:

• FDA approved 2020
• NICE approved 2022 (TA851)
• Now considered standard first-line therapy in most countries

First-Line Chemotherapy (Alternative or Sequential)

Pemetrexed + Cisplatin (Vogelzang Regimen) [17]

Regimen:

• Pemetrexed 500 mg/m² IV Day 1
• Cisplatin 75 mg/m² IV Day 1
• Cycle repeated every 21 days for 4-6 cycles
• Vitamin supplementation mandatory: Folic acid 400 μg daily + Vitamin B12 1000 μg IM every 9 weeks (reduces hematologic toxicity)

Efficacy:

• Median overall survival: 12.1 months (vs. 9.3 months cisplatin alone)
• Response rate: 41%

Indications:

• Contraindication to immunotherapy (active autoimmune disease, organ transplant)
• Patient preference
• Some centers use as sequential therapy after immunotherapy progression

Alternatives:

• Carboplatin may replace cisplatin if renal impairment or neuropathy risk
• Gemcitabine + Cisplatin: Less effective than pemetrexed regimen but may be considered

Second-Line and Beyond

Options Limited:

• Switch from immunotherapy to chemotherapy (or vice versa)
• Clinical trial enrollment strongly encouraged
• Rechallenge with immunotherapy (case-by-case basis)

Emerging Therapies (Investigational):

• ADI-PEG20 (arginine depletion, targets argininosuccinate synthetase deficiency)
• Tumor-treating fields (NovoTTF-100L device)
• Mesothelin-targeted therapies (CAR-T, antibody-drug conjugates)

Surgical Management

Paradigm Shift: MARS 1 and MARS 2 Trials

MARS 1 (2011): [18]

• Randomized feasibility study: EPP + chemotherapy vs. chemotherapy alone
• Showed no survival benefit (median OS 14.4 vs. 12.8 months)
• Higher perioperative mortality with EPP (19% at 30 days)

MARS 2 (2024): [5]

• Randomized trial: Pleurectomy/decortication vs. no surgery (both arms received chemotherapy)
• Primary finding: Surgery provided no survival benefit
  • "Median OS: 19.3 months (surgery) vs. 24.8 months (no surgery)"
• Higher perioperative morbidity and mortality
• Changed practice worldwide

Current Surgical Recommendations:

• Radical cytoreductive surgery (EPP or P/D) not recommended outside clinical trials
• Early involvement of palliative care preferred over surgical intervention

Palliative Surgical Procedures (Still Utilized):

• Pleurodesis (via thoracoscopy or talc slurry)
• Pleurectomy for trapped lung (rarely performed)
• Peritoneal mesothelioma may benefit from cytoreductive surgery + HIPEC (hyperthermic intraperitoneal chemotherapy) in highly selected cases [19]

Radiation Therapy

Palliative Radiotherapy

Indications:

• Chest wall pain from tumor invasion
• Painful subcutaneous nodules (tract metastases)
• SVC obstruction
• Hemoptysis or endobronchial obstruction

Regimen:

• Typically 20 Gy in 5 fractions or 30 Gy in 10 fractions
• Provides symptomatic relief in 60-70% of patients

Limitations:

• Large treatment volumes required
• Risk of radiation pneumonitis, esophagitis
• Limited durability of response

Hemithoracic Radiotherapy (Historical)

• Radical high-dose RT (40-50 Gy) after EPP
• Associated with significant toxicity (pneumonitis, cardiac, esophageal)
• No longer performed following abandonment of EPP

Prophylactic Tract Irradiation (PIT Trial)

Background:

• Historically, procedural tracts were irradiated to prevent seeding

PIT Trial Findings (2007): [7]

• Prophylactic RT to procedure sites did not reduce tract metastases
• No longer recommended

Pleural Effusion Management

Symptomatic pleural effusion occurs in > 90% of patients and requires intervention.

Therapeutic Thoracentesis

Indications:

• Initial diagnostic and therapeutic drainage

Technique:

• Ultrasound-guided aspiration
• Remove 1-1.5 liters (risk of re-expansion pulmonary edema if > 1.5L removed rapidly)

Limitations:

• Recurrence within 1-4 weeks in > 90% of cases
• Repeated drainage increases infection risk, patient burden

Pleurodesis

Indication:

• Re-expandable lung (confirmed on post-drainage CXR)

Technique:

• Talc poudrage (insufflation during thoracoscopy): Success rate 80-90%
• Talc slurry (via chest drain): Success rate 70-80%
• Requires apposition of visceral and parietal pleura

Contraindications:

• Trapped lung (visceral pleural peel prevents re-expansion)
• Identified by persistent pneumothorax post-drainage without air leak

Complications:

• Acute respiratory distress (talc-induced)
• Empyema
• Pain

Indwelling Pleural Catheter (IPC)

Indications: [20]

• Trapped lung (preferred option)
• Failed pleurodesis
• Limited life expectancy (less than 3 months)
• Patient preference (home drainage)

Technique:

• Tunneled silicone catheter inserted under local anesthesia
• Patient or caregiver drains 3-4 times per week

Advantages:

• Single procedure, home-based management
• Spontaneous pleurodesis occurs in 40-50% (catheter can then be removed)

Complications:

• Infection (5-10%)
• Catheter blockage
• Pneumothorax

Symptom Management and Palliative Care

Pain Management

Neuropathic Chest Wall Pain (Most Challenging):

WHO Analgesic Ladder + Adjuvants:

• Step 1: Paracetamol, NSAIDs (caution with renal impairment)
• Step 2: Weak opioids (codeine, tramadol)
• Step 3: Strong opioids (morphine, oxycodone, fentanyl)

Neuropathic Adjuvants:

• Gabapentin: 300 mg TDS, titrate to 1200-2400 mg/day
• Pregabalin: 75 mg BD, titrate to 300-600 mg/day
• Amitriptyline: 10-25 mg nocte, titrate to 75-150 mg/day
• Duloxetine: 30-60 mg daily

Interventional Options:

• Intercostal nerve blocks: Temporary relief
• Palliative radiotherapy: 20 Gy in 5 fractions
• Methadone: Reserved for refractory pain (requires specialist initiation due to NMDA antagonism and long half-life)

Dyspnoea Management

• Pleural effusion drainage (as above)
• Opioids: Morphine 2.5-5 mg PO PRN or 10-20 mg SR BD
• Benzodiazepines: Lorazepam 0.5-1 mg PRN for anxiety-associated dyspnoea
• Oxygen: If hypoxemic (SpO₂ less than 90%)
• Fan therapy: Stimulation of trigeminal nerve reduces sensation of dyspnoea

Cachexia and Anorexia

• Megestrol acetate: 160-800 mg daily (appetite stimulation)
• Corticosteroids: Dexamethasone 2-4 mg daily (short-term use)
• Nutritional support: Dietitian involvement, oral nutritional supplements

Early Palliative Care Integration

Evidence supports early palliative care involvement (concurrent with active treatment): [21]

• Improved quality of life
• Better symptom control
• Reduced aggressive end-of-life care
• May improve survival through better supportive care

---

8. Complications

Disease-Related Complications

Trapped Lung:

• Visceral pleural peel prevents lung re-expansion
• Manifests as persistent hydropneumothorax post-drainage
• Managed with IPC rather than pleurodesis

Superior Vena Cava Syndrome:

• SVC compression by mediastinal tumor
• Managed with corticosteroids, radiotherapy, rarely stenting

Pericardial Effusion and Tamponade:

• Direct pericardial invasion
• Requires pericardiocentesis, may need pericardial window

Spinal Cord Compression:

• Direct extension through intervertebral foramina
• Oncological emergency: MRI spine, dexamethasone 16 mg daily, radiotherapy

Bone Metastases:

• Less common than epithelial malignancies but can occur
• Pathological fractures, spinal instability
• Managed with radiotherapy, bisphosphonates

Treatment-Related Complications

Immunotherapy-Related:

• Pneumonitis (2-5%): Requires corticosteroids, may be life-threatening
• Colitis (5-10%): Diarrhea, abdominal pain; manage with corticosteroids ± infliximab
• Hepatitis (5%): Elevated transaminases; corticosteroids
• Endocrinopathies: Hypothyroidism (10%), hypophysitis (1-2%), adrenal insufficiency
• Dermatitis: Rash, pruritus

Chemotherapy-Related:

• Myelosuppression: Anemia, neutropenia, thrombocytopenia
• Renal toxicity: Cisplatin-induced nephrotoxicity (requires aggressive hydration)
• Peripheral neuropathy: Cisplatin dose-limiting toxicity
• Ototoxicity: High-frequency hearing loss

Procedure-Related:

• Pneumothorax: 5-15% with pleural biopsy or drainage
• Hemorrhage: Intercostal artery injury (rare with ultrasound guidance)
• Empyema: 1-5% with pleural procedures
• Tract metastases: 10-30% (prophylactic RT not beneficial)

---

9. Prognosis and Outcomes

Survival Statistics

Overall Median Survival:

• Modern era (immunotherapy available): 14-18 months
• Pre-immunotherapy era: 9-12 months

Survival by Histological Subtype:

• Epithelioid: Median 18-24 months
• Biphasic: Median 12-16 months
• Sarcomatoid: Median 8-12 months (improved to 18 months with immunotherapy)

5-Year Survival:

• Overall: 5-10%
• Epithelioid subtype: 10-15%
• Testicular mesothelioma: 50-60%

Prognostic Scoring Systems

CALGB Prognostic Score (Most Widely Used) [22]

Six Adverse Prognostic Factors:

1. Age ≥75 years
2. PS ≥1 (ECOG)
3. Sarcomatoid histology
4. Male gender
5. White blood cell count > 8.3 × 10⁹/L
6. Platelet count > 400 × 10⁹/L

Risk Groups:

• Low Risk (0-1 factors): Median survival 18-24 months
• Intermediate Risk (2-4 factors): Median survival 12-14 months
• High Risk (5-6 factors): Median survival 6-8 months

EORTC Prognostic Score

Five Adverse Factors:

1. PS ≥1
2. Leukocytosis > 8.3 × 10⁹/L
3. Non-epithelioid histology
4. Male gender
5. LDH > 500 U/L

Molecular and Genomic Prognostic Markers

BAP1 Mutation Status:

• Controversial prognostic role
• Some studies suggest worse prognosis; others show no impact

High Tumor Mutational Burden (TMB):

• Associated with better response to immunotherapy (though mesothelioma typically has low TMB)

PD-L1 Expression:

• Weak predictor of immunotherapy response (unlike in lung cancer)

---

10. Evidence and Guidelines

Key Guidelines

Landmark Evidence

1. CheckMate 743 (Lancet 2021) [4]

Trial Design:

• Phase III randomized controlled trial
• 605 patients with untreated unresectable mesothelioma
• Ipilimumab + Nivolumab vs. Pemetrexed + Cisplatin/Carboplatin

Primary Outcome:

• Overall survival: HR 0.74 (95% CI 0.60-0.91), p=0.002
• Median OS: 18.1 months (immunotherapy) vs. 14.1 months (chemotherapy)

Subgroup Analysis:

• Non-epithelioid histology: HR 0.46 (median OS 18.1 vs. 8.8 months)
• Epithelioid histology: HR 0.86 (median OS 18.7 vs. 16.5 months)

Impact:

• Changed standard of care globally
• FDA and NICE approval

2. MARS 2 (Lancet Respiratory Medicine 2024) [5]

Trial Design:

• Phase III randomized controlled trial
• Pleurectomy/decortication + chemotherapy vs. chemotherapy alone

Primary Outcome:

• Median OS: 19.3 months (surgery) vs. 24.8 months (no surgery)
• HR 1.04 (95% CI 0.76-1.42), p=0.90

Secondary Outcomes:

• Higher perioperative mortality and morbidity with surgery
• No improvement in quality of life

Impact:

• Ended widespread use of cytoreductive surgery for mesothelioma

3. Vogelzang Trial (JCO 2003) [17]

Trial Design:

• Phase III RCT: Pemetrexed + Cisplatin vs. Cisplatin alone
• 456 patients

Primary Outcome:

• Median OS: 12.1 months (combination) vs. 9.3 months (cisplatin alone)
• Response rate: 41% vs. 17%

Impact:

• Established pemetrexed-platinum as standard first-line chemotherapy (until immunotherapy era)

4. PIT Trial (Lancet Oncology 2007) [7]

Trial Design:

• Randomized trial of prophylactic radiotherapy to procedure tracts vs. no radiotherapy

Primary Outcome:

• No reduction in tract metastases with prophylactic RT

Impact:

• Abandoned routine prophylactic irradiation

---

11. Patient and Layperson Explanation

What is Mesothelioma?

Mesothelioma is a cancer that develops in the lining of the lung, called the pleura. Think of the pleura as a thin "shrink wrap" around your lung. Unlike lung cancer, which grows inside the lung tissue itself, mesothelioma grows in this outer lining.

The pleura normally produces a small amount of fluid to allow the lungs to slide smoothly when you breathe. In mesothelioma, the lining becomes thickened and scarred, and excess fluid builds up, making it hard to breathe.

Why Did This Happen? I Was Exposed to Asbestos 40 Years Ago.

Asbestos fibers are incredibly small—much thinner than a human hair—and virtually indestructible. When inhaled, they can penetrate deep into the lungs and migrate to the pleura. Your body's immune cells try to remove them but cannot break them down.

Over decades, these trapped fibers cause persistent irritation and inflammation. Eventually, this chronic damage causes cells to become cancerous. This is why there is such a long delay (typically 30-50 years) between asbestos exposure and mesothelioma diagnosis.

This delayed effect explains why we are seeing so many cases now from people who worked with asbestos during the 1970s and 1980s, when its use was at its peak.

Why Can't It Be Surgically Removed?

Unlike some cancers that grow as a single lump, mesothelioma spreads like a sheet across the entire lining of the lung. Removing it would require taking out the lung, diaphragm, and parts of the chest wall—an operation called extrapleural pneumonectomy (EPP).

Recent research trials (called MARS 2) showed that this radical surgery does not help patients live longer and causes significant complications. For this reason, surgery is rarely recommended.

What Are the Treatment Options?

The main treatment is immunotherapy, which uses medications to help your own immune system recognize and attack the cancer cells. The combination of two drugs—nivolumab and ipilimumab—has been shown to work better than older chemotherapy treatments, especially for certain types of mesothelioma.

These treatments cannot cure mesothelioma, but they can slow its growth, reduce symptoms, and extend survival. Many patients live for 18 months to 2 years or more with treatment.

What About the Fluid on My Lung?

Most people with mesothelioma develop a buildup of fluid (called a pleural effusion) that causes breathlessness. This can be drained using a small tube or needle, which usually provides immediate relief.

If the fluid keeps coming back, there are two main options:

1. Pleurodesis: A procedure where sterile talc powder is introduced into the pleural space to "glue" the lining together so fluid cannot accumulate.
2. Indwelling Pleural Catheter (IPC): A permanent, thin tube placed in your chest that allows you (or a nurse) to drain fluid at home as needed.

Will I Be in Pain?

Many people with mesothelioma experience chest pain, especially as the cancer grows into the chest wall. Pain can usually be well controlled with a combination of:

• Strong painkillers (including morphine-type medications)
• Nerve pain medications (like gabapentin)
• Radiotherapy to shrink the tumor in painful areas

Our palliative care team specializes in managing pain and other symptoms, and they will work with you throughout your treatment.

Am I Entitled to Compensation?

Yes. Because mesothelioma is almost always caused by workplace asbestos exposure, most patients are entitled to compensation. There are several pathways:

1. Industrial Injuries Disablement Benefit: A government benefit for occupational diseases (UK)
2. Civil Compensation Claims: Against former employers or asbestos manufacturers
3. Mesothelioma Lump Sum Payment: Available if your employer no longer exists or cannot be traced (UK: £24,000 as of 2024)

We will refer you to specialist legal advisors and benefits teams who can help you access these funds quickly. Fast-track legal processes exist because of the urgency of the disease.

What Can I Expect?

Mesothelioma is a serious cancer, and we cannot cure it. However, treatment can control the disease for months to years, and we will focus on maintaining your quality of life.

You will be looked after by a team of specialists including lung doctors, cancer doctors, palliative care nurses, and physiotherapists. We will support you and your family throughout this journey.

---

12. References

Primary Sources

1. Carbone M, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol. 2012;227(1):44-58. doi:10.1002/jcp.22724

2. Odgerel CO, et al. Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. Occup Environ Med. 2017;74(12):851-858. doi:10.1136/oemed-2017-104298

3. Park EK, et al. Global magnitude of reported and unreported mesothelioma. Environ Health Perspect. 2011;119(4):514-518. doi:10.1289/ehp.1002845

4. Baas P, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-386. doi:10.1016/S0140-6736(20)32714-8

5. Lim E, et al. Pleurectomy/decortication and extended pleurectomy/decortication in patients with mesothelioma (MARS 2): 3-year outcomes from a randomised trial. Lancet Respir Med. 2024;12(6):457-466. doi:10.1016/S2213-2600(23)00468-5

6. Woolhouse I, et al. British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018;73(Suppl 1):i1-i30. doi:10.1136/thoraxjnl-2017-211321

7. Boutin C, et al. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomized trial of local radiotherapy. Lancet Oncol. 2007;8(11):1001-1008. doi:10.1016/S1470-2045(07)70295-9

8. Mossman BT, et al. Asbestos: scientific developments and implications for public policy. Science. 1990;247(4940):294-301. doi:10.1126/science.2153315

9. Testa JR, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022-1025. doi:10.1038/ng.912

10. Choe N, et al. Asbestos fiber-induced generation of peroxynitrite contributes to the acute inflammatory response. Environ Health Perspect. 1998;106 Suppl 5:1127-1131. doi:10.1289/ehp.98106s51127

11. Bueno R, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407-416. doi:10.1038/ng.3520

12. Hmeljak J, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8(12):1548-1565. doi:10.1158/2159-8290.CD-18-0804

13. WHO Classification of Tumours Editorial Board. Thoracic Tumours. 5th ed. Lyon: IARC Press; 2021.

14. Hollevoet K, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012;30(13):1541-1549. doi:10.1200/JCO.2011.39.6671

15. Kawashima A, et al. CT imaging of pleural diseases. Radiographics. 2016;36(4):998-1019. doi:10.1148/rg.2016150244

16. Husain AN, et al. Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2018;142(1):89-108. doi:10.5858/arpa.2017-0124-RA

17. Vogelzang NJ, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2644. doi:10.1200/JCO.2003.11.136

18. Treasure T, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763-772. doi:10.1016/S1470-2045(11)70149-8

19. Yan TD, et al. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal mesothelioma: a systematic review. Ann Surg Oncol. 2007;14(12):3494-3501. doi:10.1245/s10434-007-9531-1

20. Davies HE, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012;307(22):2383-2389. doi:10.1001/jama.2012.5535

21. Temel JS, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-742. doi:10.1056/NEJMoa1000678

22. Curran D, et al. Prognostic factors in patients with pleural mesothelioma: the European Organisation for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16(1):145-152. doi:10.1200/JCO.1998.16.1.145

23. British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax. 2007;62 Suppl 2:ii1-ii19. doi:10.1136/thx.2007.087619

24. NICE Technology Appraisal Guidance [TA851]. Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma. National Institute for Health and Care Excellence; 2022.

---

13. Examination Focus

Common MRCP/FRACP Exam Questions

Question 1: Diagnosis

Stem: A 68-year-old former shipyard worker presents with progressive breathlessness and right-sided chest pain. CXR shows unilateral pleural effusion. Pleural fluid is blood-stained with protein 42 g/L, LDH 650 U/L. Cytology is non-diagnostic. What is the most appropriate next investigation?

Answer: Thoracoscopy with pleural biopsy

• Pleural fluid cytology has poor sensitivity (20-30%) for mesothelioma
• Tissue diagnosis with immunohistochemistry is essential
• Thoracoscopy allows direct visualization, targeted biopsies, and simultaneous pleurodesis

Question 2: Histology and Immunohistochemistry

Stem: A pleural biopsy shows malignant cells positive for Calretinin and WT-1, but negative for TTF-1 and CEA. What is the diagnosis?

Answer: Malignant mesothelioma

• Calretinin and WT-1: Mesothelial markers
• TTF-1 and CEA negativity: Excludes adenocarcinoma (lung/breast primary)
• Combination of ≥2 positive mesothelial markers and ≥2 negative carcinoma markers supports diagnosis

Question 3: First-Line Treatment

Stem: A 65-year-old man with confirmed epithelioid mesothelioma, PS 1, no autoimmune disease. What is the most appropriate first-line systemic therapy?

Answer: Ipilimumab + Nivolumab

• CheckMate 743: Immunotherapy superior to chemotherapy (median OS 18.1 vs. 14.1 months)
• Now standard of care for fit patients (PS 0-1)
• Pemetrexed-cisplatin reserved for immunotherapy contraindications

Question 4: Surgical Management

Stem: A 60-year-old with Stage II epithelioid mesothelioma, PS 0. What is the role of extrapleural pneumonectomy (EPP)?

Answer: Not recommended; no survival benefit demonstrated

• MARS 2 trial: Surgery (P/D) showed no benefit over chemotherapy alone
• Higher perioperative morbidity and mortality
• Surgery should only be performed in clinical trial context

Question 5: Trapped Lung

Stem: A patient with mesothelioma undergoes therapeutic thoracentesis. Post-drainage CXR shows a large pneumothorax but no air leak is detected. What does this indicate, and what is the best management?

Answer: Trapped lung; manage with indwelling pleural catheter (IPC)

• Trapped lung = visceral pleural peel prevents re-expansion
• Talc pleurodesis will not work (visceral and parietal pleura cannot appose)
• IPC allows intermittent drainage without need for re-expansion

Viva Voce Points

Why is Pleural Fluid Cytology Poor in Mesothelioma?

Answer: Mesothelioma cells on cytology are morphologically very similar to reactive mesothelial cells, which appear in any inflammatory pleural process (infection, trauma, pulmonary embolism). Cytology shows individual cells in suspension but cannot assess tissue architecture or demonstrate invasion into underlying fat or muscle, which is the histological hallmark of malignancy. Only a tissue biopsy can definitively prove invasion.

Describe the Mechanism of "Frustrated Phagocytosis"

Answer: Asbestos fibers are too long for macrophages to fully engulf (typically > 10 μm length). Macrophages attempt phagocytosis but fail, remaining chronically activated. They continuously release:

• Reactive oxygen species (ROS), causing DNA damage
• Pro-inflammatory cytokines (TNF-α, IL-1, IL-6)
• Growth factors (PDGF, TGF-β) promoting fibrosis

This cycle persists for decades, creating a mutagenic environment that eventually leads to transformation of mesothelial cells.

What is the Significance of BAP1 Mutations?

Answer: BAP1 (BRCA1-Associated Protein 1) is a tumor suppressor gene mutated in > 60% of mesotheliomas. It encodes a deubiquitinating enzyme involved in DNA repair and chromatin remodeling.

• Somatic mutations: Occur in sporadic mesothelioma
• Germline mutations: Cause BAP1 tumor predisposition syndrome, with increased risk of:
  • Mesothelioma (even with minimal asbestos exposure)
  • Uveal melanoma
  • Cutaneous melanoma
  • Renal cell carcinoma

Loss of BAP1 expression on immunohistochemistry is highly specific for mesothelioma and helps distinguish it from reactive mesothelium.

Why Does Immunotherapy Work Better in Sarcomatoid Mesothelioma?

Answer: This is somewhat paradoxical, as sarcomatoid tumors typically have "immune cold" phenotypes. The CheckMate 743 trial showed a hazard ratio of 0.46 for non-epithelioid histology with immunotherapy vs. chemotherapy (median OS 18.1 vs. 8.8 months).

Hypotheses include:

• Higher neoantigen burden in sarcomatoid tumors due to genomic instability
• Epithelial-mesenchymal transition (EMT) in sarcomatoid tumors may make them more susceptible to immune-mediated killing once checkpoint blockade is released
• Chemotherapy resistance makes the chemotherapy arm perform particularly poorly, exaggerating the benefit of immunotherapy

The exact mechanism remains under investigation.

What is the Role of Mesothelin as a Biomarker?

Answer: Mesothelin is a cell-surface glycoprotein overexpressed in mesothelioma (and some other cancers like ovarian and pancreatic adenocarcinoma).

Serum Mesothelin-Related Peptide (SMRP):

• Elevated in 60-80% of mesotheliomas
• Not suitable for screening due to low sensitivity and specificity
• Useful for monitoring treatment response and detecting recurrence
• Elevated in benign conditions (renal failure, pleural inflammation), reducing diagnostic utility

Therapeutic Target:

• Anti-mesothelin CAR-T cells, antibody-drug conjugates, and vaccines are in clinical trials

High-Yield Exam Mnemonics

Asbestos Fiber Types (Most to Least Dangerous): "CABA"

• Crocidolite (Blue) - most dangerous
• Amosite (Brown)
• Anthophyllite
• Chrysotile (White) - least dangerous

Mesothelioma IHC Panel (Positive Markers): "CalWD" = Calretinin, WT-1, D2-40

Poor Prognostic Factors (CALGB Score): "AMAS-PP"

• Age ≥75
• Male
• Anemia (low Hb)
• Sarcomatoid histology
• Platelets > 400
• Performance status ≥1

---

14. Future Directions and Research

Emerging Therapies

ADI-PEG20 (Arginine Depletion):

• Exploits argininosuccinate synthetase deficiency in mesothelioma cells
• Phase II/III trials ongoing

Tumor-Treating Fields (TTFields):

• NovoTTF-100L device applies alternating electric fields
• STELLAR trial (Phase III) reported negative results in 2023

Mesothelin-Targeted Therapies:

• CAR-T cells targeting mesothelin
• Antibody-drug conjugates (Anetumab ravtansine)
• Cancer vaccines

Novel Immunotherapy Combinations:

• PD-1/PD-L1 inhibitors + anti-CTLA-4 + chemotherapy (triplet regimens)
• Oncolytic viruses + checkpoint inhibitors

Biomarker Development

Liquid Biopsy:

• Circulating tumor DNA (ctDNA) for early detection and monitoring
• Methylation signatures distinguishing mesothelioma from benign pleural disease

Predictive Biomarkers:

• Better predictors of immunotherapy response (beyond PD-L1)
• Molecular subtyping to guide treatment selection

Prevention and Early Detection

Global Asbestos Ban:

• ~70 countries have banned asbestos, but major producers (Russia, China, India) continue mining and export
• Advocacy for global ban continues

Screening in High-Risk Populations:

• No effective screening method currently exists
• Annual low-dose CT trials in heavily exposed cohorts underway
• Blood-based biomarker panels under investigation

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines.